Welcome
Support Centre
01 August 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Biomarker-supported detection of paroxysmal atrial fibrillation in patients with cerebral ischemia.
ISRCTN ISRCTN46104198
DOI 10.1186/ISRCTN46104198
ClinicalTrials.gov identifier
EudraCT number
Public title Biomarker-supported detection of paroxysmal atrial fibrillation in patients with cerebral ischemia.
Scientific title A longitudinal cohort study in patients presenting with acute cerebral ischemia to identify factors that are predictive individually or in combination for a diagnosis of atrial fibrillation during 12 months of follow-up.
Acronym Find-AF
Serial number at source Protocol 23/11/08 EC UMG
Study hypothesis Novel biomarkers will improve the diagnosis of paroxysmal atrial fibrillation in patients presenting with cerebral ischemia.
Lay summary Not provided at time of registration
Ethics approval Approved by local ethics committee of the medical faculty of the university of Goettingen, Germany, on the 27th of January 2009 (ref: 23/11/08)
Study design Single centre observational longitudinal cohort study
Countries of recruitment Germany
Disease/condition/study domain Cerebral ischemia, Atrial fibrillation
Participants - inclusion criteria 1. Cerebral ischemia, i.e. transient ischemic attack (TIA) or stroke
2. Ability and willingness to consent
3. Age > 18 years
Participants - exclusion criteria 1. Inability or unwillingness to consent
2. Age < 18 years
3. Cerebral haemorrhage
Anticipated start date 01/03/2009
Anticipated end date 28/02/2011
Status of trial Completed
Patient information material
Target number of participants 300 included
Interventions Serial biomarker sampling for the identification of novel biomarkers to be used in the diagnosis of atrial fibrillation.
Blood samples will be collected at 0, 6 and 12 hours after presentation. The primary marker will be the value of the change of natriuretic peptides over time after presentation, calculated as ratio N-terminal pro B-type Natriuretic Peptide (NT-proBNP) at 0h / NT-proBNP at 24h.
All patients will also undergo transthoracic echocardiography.

7-day Holter monitoring, 90-day telephone follow-up and 12 months clinical follow-up will be used to optimize detection of atrial fibrillation as the endpoint for which blood markers, clinical characteristics and echocardiographic markers may show prognostic value.
Primary outcome measure(s) Diagnosis of atrial fibrillation from baseline up to 12 months follow-up
Secondary outcome measure(s) Major adverse cerebral or cardiovascular events (MACCE)
Sources of funding University Hospital Goettingen (Germany) - Department of Cardiology and Pneumology
Trial website
Publications 1. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20966415
2. 2013 results in http://www.ncbi.nlm.nih.gov/pubmed/23840747
3. 2013 cost-effectiveness results in http://www.ncbi.nlm.nih.gov/pubmed/23904073
Contact name Dr  Raoul  Stahrenberg
  Address Department of Cardiology and Pneumology
University Hospital Goettingen
Robert-Koch-Str. 40
  City/town Goettingen
  Zip/Postcode 37075
  Country Germany
  Email stahrenberg@med.uni-goettingen.de
Sponsor University Hospital Goettingen (Germany) - Department of Cardiology and Pneumology
  Address Robert-Koch-Str. 40
  City/town Goettingen
  Zip/Postcode 37075
  Country Germany
  Email wachter@med.uni-goettingen.de
  Sponsor website: http://www.herzzentrum-goettingen.de
Date applied 04/01/2010
Last edited 02/08/2013
Date ISRCTN assigned 17/02/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.